Trials / Completed
CompletedNCT00189267
A Study to Evaluate the Effectiveness and Safety of Multiple Applications of Imiquimod 5% Cream for the Treatment of Actinic Keratoses in Organ Transplant Recipients
Vehicle-Controlled, Double-Blind Study to Assess the Safety and Efficacy of Imiquimod 5% Cream Applied Once Daily 3 Days Per Week for the Treatment of Actinic Keratoses in Immunosuppressed Organ Transplant Recipients.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 45 (planned)
- Sponsor
- MEDA Pharma GmbH & Co. KG · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to compare effectiveness and safety of multiple applications of imiquimod 5% cream and vehicle cream in graft recipients suffering from actinic keratosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Imiquimod 5 % Cream |
Timeline
- Start date
- 2002-11-01
- Completion
- 2005-09-01
- First posted
- 2005-09-19
- Last updated
- 2022-02-07
Source: ClinicalTrials.gov record NCT00189267. Inclusion in this directory is not an endorsement.